Justificación del estudio. Las concentraciones plasmáticas, tanto de interferón pegilado-alfa (PegIFN-alfa) como ribavirina (Rbv), se caracterizan por presentar una amplia variabilidad interindividual tras su administración a dosis estándares. Por otro lado, puesto que la inhibición de la replicación in vitro del VHC con IFN-alfa es...
-
April 26, 2017 (v1)PublicationUploaded on: December 4, 2022
-
July 2, 2021 (v1)Publication
Background: The aim of the study was to analyze the different impact of standard and low-dose Peg-IFN-a2a/RBV therapies on HCV viral decline in HIV/HCV genotype 3 co-infected patients during the first weeks of treatment. Methods: Plasma HCV viral decline was analyzed between baseline and weeks 1, 2 and 4 in two groups of treatment-naı¨ve HCV...
Uploaded on: December 4, 2022 -
July 5, 2021 (v1)Publication
Objective: To establish the role of liver fibrosis as a predictive tool of response to pegylated interferon alpha (Peg-IFN) and ribavirin (RBV) treatment in human immunodeficiency (HIV)/hepatitis C virus (HCV) coinfected patients, in addition to recognized predictive factors (HCV load, HCV genotype, IL-28B polymorphism). Patients and Methods: A...
Uploaded on: December 4, 2022